Moderna has announced the conclusion of construction works at its new respiratory messenger ribonucleic acid (mRNA) manufacturing facility in Canada, a significant step towards enhancing the country’s readiness for future pandemics.
The facility in Laval, Quebec, is scheduled to begin producing mRNA vaccines in 2025.
The establishment of the Laval site is a pivotal development in Moderna’s partnership with the Canadian Government, aimed at bolstering domestic pandemic preparedness.
The partnership underscores a commitment to meet the highest standards of vaccine quality, safety and efficacy.
The project, partly funded by the Quebec government through Investissement Québec, will create and sustain high-skilled jobs in the region.
Moderna CEO Stéphane Bancel stated: “With infectious diseases continuing to pose a significant health challenge, our mRNA platform can play a pivotal role against current and future threats.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
“Canada’s role in global health is critical, and with this facility, Moderna is honoured to contribute to its robust scientific community and public health leadership in driving innovation and transformative medicine forward.”
Moderna’s investment in Quebec aligns with its environmental sustainability goals, with the facility designed to minimise fossil fuel usage and leverage the province’s renewable energy sources.
The Laval manufacturing site is part of the company’s broader strategy to address global health challenges. It has 45 programmes in its portfolio, including nine in advanced stages of development, in infectious diseases, immuno-oncology, rare diseases and autoimmune disorders.
Moderna Canada general manager Stefan Raos stated: “Completing the construction of our mRNA facility marks a groundbreaking moment for Moderna and Canada as we progress towards delivering a domestic mRNA vaccine supply chain.
“This building is a tangible example of concerted collaboration with the federal government, the government of Quebec and the city of Laval, reflecting the lessons of the pandemic.”
The latest development comes after the company reported a net loss of $4.7bn for the full year 2023 against net income of $8.4bn in 2022.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
